## **Amendments to the Drawings:**

The attached sheets of drawings includes changes to Figs. 1, 2, 3 and 4. These sheets, which include Figs. 1, 2, 3 and 4 replace the original sheets including Figs. 1, 2, 3 and 4.

Attachments: Replacement Sheets (Fig. 1, sheets 1-5, Fig. 2, sheets 1-2, Fig. 3, sheets 1-6 and Figs. 4A, 4B, 4C and 4D)

Annotated Sheets Showing Changes (Fig. 1, sheets 1-4, Fig. 2, sheets 1-2, Fig. 3, sheets 1-7 and Figs. 4A, 4B, 4C and 4D)

## **REMARKS**

In the Office Action mailed June 23, 2008, the Examiner indicated that "Specification page 13 contains a sequence recitation that is not included in the Sequence Listing" and "applicant is advised to add the sequences of all of the illustrated strains in figures 1-4 to the Sequence Listing." Applicants have reviewed all submitted application materials of the Specification and Figures and have made the appropriate additions and corrections to the Substitute Sequence Listing and in the Specification by the enclosed Amendment.

The sequences found in amended paragraphs [49], [53], [58] and [163] have been included in the Substitute Sequence Listing as oligonucleotides where a 6-carboxyfluorescein (FAM) moiety is integrated into the sugar-phosphate backbone of the nucleotide as a base analog (represented as "I" in the interior of these sequences). Since this residue cannot be represented in the Sequence Listing as a nucleotide, and the sequence immediately 5' to the "I" residue is less than 10 nucleotides in length, the nucleotide immediately 3' to the "I" symbol has been described in the "Feature" section as a "modified\_base" at position 1, where the entire portion of the sequence 5' to this residue forms the base modification.

The drawings for Figures 1-4 have been amended pursuant to the provisions of 37 C.F.R. § 1.84 and 1.121(d). In Figures 1 and 2, the sequence identifier on the top line has been corrected to conform to the sequence identifier provided for these sequences in the "BRIEF DESCRIPTION OF THE DRAWINGS" for Figures 1 and 2 on page 16.

In Figure 3, in addition to amending the sequence identifiers, the sequence information on replacement sheets 1-6 has corrected word processing errors resulting in "wrap-around" of the sequence portions indicated on the annotated copies of Figure 3, sheets 1-7.

Figs. 4C and 4D have inserted the description of the "Kunjin" virus preceeding the GenBank Accession No. "L24512" at the end of the list of West Nile virus ("WNV") sequences at the top of these figures, conforming to the listing of "L24512" under "KUNJIN" in e.g., Fig. 4B, third from the bottom, and elsewhere in Figs. 1-3. In addition, the "L24512" entry under "JEV" in Fig. 4D has been omitted, since it is properly represented under "Kunjin".

Appl. No. 10/815,480 Amdt. dated August 22, 2008 Reply to Office Action of June 23, 2008

Further, the instant amendments to paragraphs [70]-[74] insert the additional corrected sequence identifiers at the proper locations in the Specification for the sequences added to the Substitute Sequence Listing from Figures 1-5, per the request of the Examiner.

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a computer readable form containing the above named sequences, SEQ ID NOS:1-920, and a paper copy of the sequence information which has been printed from the computer readable form.

The information contained in the computer readable form was prepared through the use of the software program "FastSEQ" and is identical to that of the paper copy. This amendment contains no new matter.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Matthew E. Hinsch Reg. No. 47,651

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300 Attachments

MEH:dmw 61474254 v1